My Alcon | Canada

This page is available in English. Select below for other countries.

Select Another Country

 

Clareon® Collection IOLs

 

More options for more patients:
four optic designs, one glistening-free* material1-3

 

Clareon® Collection IOLs

 

More options for more patients:
four optic designs, one glistening-free* material1-3

 

 

The Clareon® IOL portfolio offers the latest material advancement in a 20+ year history of continual innovation in IOLs.

Presbyopia-Mitigating IOLs

 

Help reduce the need for glasses at all distances3-5 on a glistening-free* BioMaterial.1,2


Clareon® PanOptix® IOL

 

The Gold Standard in trifocal technology, offering a full range of vision and exceptional clarity.4,6**  

 

LEARN MORE

 

Alt text


Clareon® Vivity® IOL

 

The first and only non-diffractive presbyopia-mitigating technology with exceptional clarity.1,5*

 

LEARN MORE

Alt text

Monofocal IOLs

 

Glistening-free* BioMaterial with outstanding clarity**, for sharp, crisp vision.1,2,7


Clareon® Toric® IOL

 

Manage astigmatism with unrivaled axial and rotational stability.8  

 

LEARN MORE

Alt text


Clareon® Monofocal IOL

 

Exceptional clarity,** allowing you to confidently deliver long-lasting refractive outcomes.1,2 

 

LEARN MORE

Alt text

The latest evolution of control and clarity with the Clareon® Monarch® IV and
Clareon® AutonoMe® IOL delivery systems

Clareon® Monarch® IV Delivery System

 

Monarch® IV manual delivery system designed specifically for Clareon® IOLs provides reliability, control and user comfort.9,10

 

LEARN MORE

Alt text

Clareon® AutonoMe® IOL Delivery System

 

AutonoMe® preloaded IOL delivery system provides easy, intuitive control for precise IOL insertion.11

 

LEARN MORE

Alt text

See the difference Clareon® can make

 

An advanced manufacturing process combines a proprietary precision edge design with the exceptional BioOptics and BioMechanics of all Alcon IOLs.12

Peer perspectives on Clareon®

 

Learn more about your peers' experience with the Clareon® Collection of IOLs.

Clareon® AutonoMe® IOL Delivery System

 

DOWNLOAD PATIENT BROCHURES

 

Alt text

Available on Clareon®: Alcon’s Most Advanced IOL BioMaterial to Date

Alt text

IMPORTANT PRODUCT INFORMATION - CLAREON® ASPHERIC FAMILY OF HYDROPHOBIC ACRYLIC IOLS

CAUTION: Federal law restricts these devices to sale by or on the order of a physician.

INDICATIONS: The family of Clareon® intraocular lenses (IOLs) includes the Clareon® Aspheric Hydrophobic Acrylic and Clareon® Aspheric Toric IOLs, the Clareon® PanOptix® Trifocal Hydrophobic IOL, Clareon® PanOptix® Toric, Clareon® Vivity® Extended Vision Hydrophobic Posterior Chamber IOL and Clareon® Vivity® Toric IOLs. Each of these IOLs is indicated for visual correction of aphakia in adult patients following cataract surgery. In addition, the Clareon® Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery. The Clareon® PanOptix® lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. The Clareon® Vivity® lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity. All of these IOLs are intended for placement in the capsular bag. 

WARNINGS / PRECAUTIONS: General cautions for all Clareon® IOLs: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Physicians should target emmetropia and ensure that IOL centration is achieved.     
For the Clareon® Aspheric Toric, PanOptix® Toric and Vivity® Toric IOLs, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged, or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction; if necessary, lens repositioning should occur as early as possible prior to lens encapsulation.    
 

For the Clareon® PanOptix® IOL, some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or starbursts, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions. Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning). As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO), may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs.    
 

For the Clareon® Vivity® IOL, most patients implanted with the Vivity® IOL are likely to experience significant loss of contrast sensitivity as compared to a monofocal IOL. Therefore, it is essential that prospective patients be fully informed of this risk before giving their consent for implantation of the Clareon® Vivity® IOL. In addition, patients should be warned that they will need to exercise caution when engaging in activities that require good vision in dimly lit environments, such as driving at night or in poor visibility conditions, especially in the presence of oncoming traffic. It is possible to experience very bothersome visual disturbances, significant enough that the patient could request explant of the IOL. In the parent AcrySof® IQ Vivity® IOL clinical study, 1% to 2% of AcrySof® IQ Vivity® IOL patients reported very bothersome starbursts, halos, blurred vision, or dark area visual disturbances; however, no explants were reported.    
 

Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon informing them of possible risks and benefits associated with these IOLs. 

ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.

REFERENCES:

 

  1. Werner L, Thatthamla I, Ong M, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL. J Cataract Refract Surg. 2019;45: 1490-1497.
  2. Oshika T, Fujita Y, Inamura M, Miyata K. Mid-term and long-term clinical assessments of a new 1-piece hydrophobic acrylic IOL with hydroxyethyl methacrylate. J Cataract Refract Surg. 2020 May;46(5):682-687.
  3. Maxwell A and Suryakumar R. Long-term effectiveness and safety of a three-piece acrylic hydrophobic intraocular lens modified with hydroxyethyl-methacrylate: an open-label, 3-year follow-up study. Clin Opthalmol. 2018;12:2031–2037.
  4. Zhu D, Ren S, Mills K, Hull J, Dhariwal M. Rate of Complete Spectacle Independence with a Trifocal Intraocular Lens: A Systematic Literature Review and Meta-Analysis. Ophthalmol Ther. 2023;12(2):1157-1171.
  5. Clareon® Vivity® Extended Vision Hydrophobic IOL (CNWET0) Directions for Use – USA. 
  6. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL Model CNWTT0 2021 Directions for Use.
  7. Alcon Data on File, 2019.
  8. Clareon® Toric Directions for Use.
  9. Clareon® Monarch® IV Directions for Use.
  10. Alcon Data on File, 2019.
  11. Clareon® AutonoMe® IOL Directions for Use.
  12. Das KK, Werner L, Collins S, Hong X. In vitro and schematic model eye assessment of glare or positive dysphotopsia-type photic phenomena:Comparison of a new material IOL to other monofocal IOLs. J Cataract Refract Surg. 2019;45(2):219-227.